Herbs (Global Traditional) · African
Xysmalobium undulatum
Moderate Evidencebotanical
Hermetica Superfood Encyclopedia
Xysmalobium undulatum is a Southern African medicinal plant containing cardiac glycosides that exhibits antisecretory properties in the digestive tract. The root extract demonstrates antidiarrheal activity by reducing intestinal fluid secretion through inhibition of chloride channels.
Xysmalobium undulatum, commonly known as uzara, is a perennial herbaceous plant native to southern Africa, particularly South Africa, belonging to the Asclepiadaceae family. The medicinal parts are primarily the roots, from which extracts are prepared using water or aqueous methods to yield crude extracts containing cardenolide glycosides.
No human clinical trials, RCTs, or meta-analyses are detailed in the available sources, with multiple reviews explicitly stating that clinical trial data is lacking. Evidence is limited to in vitro and in vivo animal studies confirming antisecretory antidiarrheal action. One literature review mentions efficacy supported by clinical trials but provides no specific study details or PMIDs.
No clinically studied dosage ranges are available due to the absence of human clinical trials. Commercial uzara products exist, but standardization details and specific dosages from studies are not provided. Consult a healthcare provider before starting any new supplement.
Xysmalobium undulatum (commonly known as 'Uzara' or 'wild cotton') is not consumed as a food but rather as a medicinal plant, so a conventional macronutrient profile (calories, carbohydrates, protein, fat) is not typically characterized. Its significance lies in its bioactive phytochemical constituents, primarily found in the dried root and rhizome: • **Cardenolide glycosides (cardiac glycosides):** The principal active compounds, present at approximately 1.5–4% total glycoside content in dried root material. Key individual glycosides include: – **Uzarin** (major glycoside, approximately 0.5–1.5% of dried root) – a steroidal glycoside structurally related to digitalis compounds – **Xysmalobin** (approximately 0.3–0.8% of dried root) – **Allouzarin** and other minor uzarigenin-derived glycosides • **Uzarigenin:** The aglycone (sugar-free) backbone of the major glycosides; approximately 0.1–0.3% in free form in dried root; serves as the pharmacologically active steroidal moiety responsible for antisecretory and antispasmodic effects • **Pregnane glycosides:** Minor quantities of pregnane-type steroidal glycosides have been identified, contributing to the overall bioactivity profile • **Phenolic compounds and tannins:** Present in modest amounts (estimated 1–3% of dry weight), contributing mild antioxidant and astringent properties • **Saponins:** Low to moderate levels detected in root extracts, potentially contributing to gastrointestinal activity • **Minerals (trace):** As a root material, it contains trace minerals including potassium, calcium, and magnesium, though these are not present in pharmacologically significant quantities when consumed in typical medicinal doses (standardized preparations deliver ~15–45 mg of total glycosides per dose) • **Fiber:** The raw root contains plant cellulose and hemicellulose typical of tuberous roots, but this is largely irrelevant in standardized extract preparations • **Bioavailability notes:** Uzarin and xysmalobin are orally bioavailable; the sugar moieties (glucose, rhamnose) attached to the aglycone uzarigenin modulate absorption kinetics. Oral bioavailability of the intact glycosides is moderate, with partial hydrolysis to uzarigenin occurring in the gastrointestinal tract. The therapeutic window is narrow due to the cardiac glycoside nature of the compounds — standardized dosing is critical. Commercial preparations (e.g., Uzara® tablets) are standardized to total glycoside content to ensure safety and efficacy.
Xysmalobium undulatum contains cardiac glycosides that inhibit intestinal chloride channels, reducing fluid secretion into the bowel lumen. The antisecretory action occurs through modulation of cAMP-mediated chloride transport in intestinal epithelial cells. This mechanism helps reduce diarrheal symptoms by decreasing excessive fluid loss.
Current evidence for Xysmalobium undulatum is limited to in vitro and animal studies demonstrating antisecretory antidiarrheal effects. No human clinical trials have been conducted to validate the traditional uses for stomach cramps or dysmenorrhea management. Animal studies show measurable reduction in intestinal fluid secretion, but specific sample sizes and effect magnitudes are not well documented. The evidence remains preliminary and requires human clinical validation.
Safety data for Xysmalobium undulatum is extremely limited with no established human safety profile. The presence of cardiac glycosides raises concerns about potential cardiac effects and interactions with heart medications like digoxin. Pregnancy and breastfeeding safety is unknown and should be avoided. No documented drug interactions exist, but caution is advised with cardiac medications due to glycoside content.
